VISION2030 targets for the domestic platform, overseas profits and new products
First written in FY2024. 2 of 3 entries say "Restated". Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1RestatedAnnual report
「To manage the business from a long-term perspective, the group has established “VISION2030” as its target vision toward 2030, comprising 3 pillars: “Japan’s leading medical device trading company,” “generate 20% of operating profit from overseas,” and “launch 30 or more new products and services.” It is proceeding with efforts to build the foundation for achieving these goals.」
The company continues to present the 3 pillars of VISION2030 toward 2030, along with the targets of generating 20% of operating profit overseas and launching 30 or more new products and services. - FY2025-H1RestatedAnnual report
「The group has newly established “VISION2030” as its target vision toward 2030, comprising 3 pillars: “Japan’s leading medical device trading company,” “generate 20% of operating profit from overseas,” and “launch 30 or more new products and services.” It has begun building the foundation for achieving these goals.」
The company continues to present the 3 pillars of VISION2030 toward 2030, together with the targets of generating 20% of operating profit overseas and launching 30 or more new products and services, in its interim disclosure. - FY2024First statedAnnual report
「The group has established “VISION2030” as its target vision toward 2030. Its details are as follows: 1) Aim to become Japan’s leading medical device trading company; 2) generate 20% of operating profit from overseas; and 3) launch 30 or more new products and services.」
The company disclosed for the first time its long-term vision toward 2030, setting out 3 directions and targets covering its domestic position, the proportion of operating profit generated overseas, and the number of new products and services launched.